Brain tumor is one of the diagnoses most feared by patients, physicians,
and even oncologists. Their fear is justified. More than half of the 18 400
primary malignant brain tumors diagnosed each year in the United States are
malignant gliomas1 that not only confer high
risk for death and severe disability, but also steal what is held so highly
as the essence of human life: the mind and spirit. In this issue of JAMA, Chang et al2 use data
from the Glioma Outcomes (GO) Project to provide a “report card”
on the patterns of care in patients with newly diagnosed malignant gliomas;
unfortunately, the grades are sobering. Consequently, this is an appropriate
time to reflect on the past and current status of glioma treatment and suggest
where to go from here.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 35
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.